Aarti Drugs share price today

Aarti Drugs Ltd's share price was ₹455.80 at the close on 4 November 2026. It has been rising for 10 weeks. That is 11.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹331 and ₹491, and at that close it sat 78% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Aarti Drugs Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row.

Over the last 11 years the share price moved +274% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: revenue up on a year earlier for 6 quarters in a row.

1. Revenue up on a year earlier for 6 quarters in a row

   In the June 2026 quarter revenue was ₹703 crore, +19% on a year earlier.

   Why: Revenue rose because the company got better prices for its main drug ingredients and sold more of them.

   Next results: check whether customer inventories reset and volume growth improves.

   From the earnings call on 3 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Aarti Drugs reported revenue of ₹703 crore, up 19.0% from ₹591 crore a year earlier, and a profit of ₹50.0 crore, down 7.4% from ₹54.0 crore.

Aarti Drugs results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Aarti Drugs' management discussed these results on a call held on 3 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Aarti Drugs closed at ₹455.80 on 4 November 2026, down 7.3% from ₹491.45 a year earlier (7 November 2025) and down 21.0% over five years. Its highest weekly close since March 2016 was ₹984.40 on 9 October 2020.

Aarti Drugs share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Aarti Drugs closed at ₹455.80, up 4.6% on the week and up 8.0% on the month. 3 Aug 2026: Aarti Drugs held its results call for April to June 2026. Management guided: 15.0% consolidated operating margin once greenfield utilization improves and salicylic drag reduces; the current underlying level was described as achievable.

Earlier

• Results for April to June 2026: Revenue up 19.0% and profit down 7.4% on a year earlier.
• 9 Feb 2026: ex-date for an interim dividend of ₹2 a share.

Aarti Drugs paid ₹2 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.44% at the ₹455.80 close on 4 November 2026. The last was an interim dividend of ₹2 a share, ex-date 9 February 2026.

Aarti Drugs dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Aarti Drugs Ltd paid out 9% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 3 August 2026, Aarti Drugs' management guided: 15.0% consolidated operating margin once greenfield utilization improves and salicylic drag reduces; the current underlying level was described as achievable.

“The US market has not started yet, but business development has already started. We have already sent samples to customers for approval.”Adish Patil, on the call for April to June 2026

What management guided

• Volume growth of 10.0-15.0% over the next 2 years; 10.0% remains achievable without salicylic derivatives.
• Sarigam Metformin capacity to scale from 1,400 to 2,200 tons per month, including 500-550 USFDA capacity; construction takes 10-12 months and first US supplies are expected after 18-24 months.
• Specialty chemicals performance is expected to repeat and improve through the remaining quarters; Sayakha captive consumption should reach 80.0-90.0% by the September and December quarters, adding about 1.0% to gross contribution at peak utilization.
• Baddi solid-dosage capacity is expected to nearly double; adjacent E22 USFDA capacity should more than double through 3 multipurpose lines of about 10 tons per month each; Phase 1 and Phase 2 asset turnover is expected at 1.5x and 3.0-4.0x over the next 2-3 years.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 3 August 2026.

When Aarti Drugs reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Sayakha operating streamlining and utilization ramp - check whether captive integration advances without interruption.

Aarti Drugs is on 2 of our India lists: Momentum stocks and Pharma stocks.

Aarti Drugs Ltd earned ₹50.0 Cr of net profit in the Jun 2026 quarter, −7.4% on the same quarter a year earlier. Full-year FY26 profit was ₹195 Cr. Over 10 years profit has grown 10.9% a year on average. That is 7.1% of the quarter's revenue. The same quarter a year earlier earned ₹54.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹195 Cr (+16.1% on the year before).

Why profit moved: revenue changed +19.0% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +4.8% and revenue +10.7%. Profit is growing slower than sales: rising costs are taking part of the growth.

Aarti Drugs Ltd reported ₹703 Cr of revenue in the Jun 2026 quarter, +19.0% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 8.4% a year on average. The last full year, FY26, came in at ₹2,565 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹2,678 Cr.

FY26 revenue was ₹2,565 Cr, +7.5% on the year before.

Recent pace: the last four quarters grew +10.7% on average, against 8.4% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +10.5%, against +5.1% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +1.1%, against +10.3% a year (rolling over).

Aarti Drugs Ltd's operating margin was 14.0% in the Jun 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 11.0% and 20.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +1.4 percentage points on the year while gross margin changed +2.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 160% of Aarti Drugs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹254 Cr of operating cash against ₹195 Cr of profit. After ₹171 Cr of spending on assets, ₹83.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 160% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: the bigger use of cash is spending on new assets, at 3.4× depreciation over three years. The next section checks what that spending is building.

Aarti Drugs Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 121 days in FY26, up from 118 days in FY21. It spent ₹588 Cr on assets over the last 3 years. Customers take 118 days to pay, and stock sits for 112 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,565 Cr, each day of that cycle ties up about ₹7.0 Cr, so roughly ₹850 Cr is tied up in the business at any time.

FY26: customers took 118 days to pay and stock sat for 112 days, about 3.7 months of sales sitting as stock, for a full cycle of 121 days, longer than FY21's 118.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 112 days. Customers pay about 118 days after that. Suppliers are paid at 109 days. Together that makes the 121-day cycle.

Spending on assets: ₹588 Cr over the last 3 years, against ₹174 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹214 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Aarti Drugs Ltd's P/E is 21.6×, in the middle of its own history: higher than 56% of past readings. Its usual P/E (the middle reading) is 20.4×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.